New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 22, 2014
06:25 EDTBMY, AZNAstraZeneca, Bristol-Myers say Xigduo approved in the EU for type 2 diabetes
AstraZeneca (AZN) and Bristol-Myers Squibb (BMY) announced that Xigduo has been granted Marketing Authorization by the European Commission for the treatment of type 2 diabetes in the European Union. Xigduo combines dapagliflozin, a selective and reversible inhibitor of SGLT2 with metformin hydrochloride, two anti-hyperglycaemic products with complementary mechanisms of action to improve glycaemic control, in a twice daily tablet. This is the first regulatory approval for a fixed dose combination of an SGLT2 inhibitor and metformin. Xigduo is indicated for adults aged 18 and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control.
News For AZN;BMY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 27, 2015
08:19 EDTBMYBristol-Myers announces ALLY-1 trial met primary endpoints
Subscribe for More Information
06:19 EDTBMY, AZNPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 24, 2015
08:09 EDTBMYBristol-Myers May weekly volatility elevated into Q1 and outlook
Bristol-Myers May weekly call option implied volatility is at 27, May is at 21, June is at 22, September is at 22; compared to its 26-week average of 22 according to Track Data, suggesting large near term price movement into the expected release of Q1 results on April 28.
07:47 EDTBMYBristol-Myers receives positive CHMP opinion in EU for Opdivo
Subscribe for More Information
06:19 EDTAZNAstraZeneca says smaller M&A deals more realistic, Reuters reports
Subscribe for More Information
06:07 EDTAZNAstraZeneca reiterates outlook for FY15
Subscribe for More Information
06:06 EDTAZNAstraZeneca reports Q1 core EPS $1.08, consensus $1.05
Reports Q1 revenue $6.06B, consensus $5.95B. Reports Q1 Symbicort revenue $845M vs. $928M last year, Pulmicort revenue $286M vs. $263M last year, Crestor revenue $1.17B vs. $1.33B last year, Nexium revenue $644M vs. $930M last year.
05:39 EDTAZNCelgene announces strategic collaboration with AstraZeneca
Subscribe for More Information
05:37 EDTAZNAstraZeneca signs co-development agreement with Innate Pharma
Subscribe for More Information
April 23, 2015
15:01 EDTAZNNotable companies reporting before tomorrow's open
Subscribe for More Information
08:25 EDTAZNJuno Therapeutics, MedImmune announce immuno-oncology trial collaboration
Subscribe for More Information
April 22, 2015
08:04 EDTAZNBIND Therapeutics presents data on BIND-014, AZD2811 at AACR
Subscribe for More Information
07:07 EDTBMYEuropean Association for the Study of the Liver to hold annual meeting
50th Annual Meeting of EASL will be held in Vienna, Austria on April 22-26.
April 21, 2015
10:00 EDTBMYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:06 EDTAZNBina Tech, AstraZeneca announce collaborative agreement for GMS
Bina Technologies, a member of the Roche Group (RHHBY), and AstraZeneca (AZN) announced that they have entered into an agreement for AstraZeneca to become the first member to join the Bina Alliance Program and to further develop the Bina Genomic Management Solution. AstraZeneca will utilize the Bina GMS as an enterprise platform to support its development work across three main therapeutic areas: oncology, cardiovascular and metabolic disease, and respiratory, inflammation and autoimmunity. Bina’s proprietary technology enables translational and academic researchers to perform fast and scalable analyses to maximize the value of genomic data. Under the terms of the agreement, AstraZeneca will adopt Bina GMS globally to support enterprise genomic data analysis and management. Bina in turn will provide AstraZeneca with direct access to its scientific and engineering teams to further develop the Bina GMS for pharmaceutical applications.
06:44 EDTBMYBristol-Myers upgraded on early Opdivo success at Morgan Stanley
As previously reported, Morgan Stanley upgraded Bristol-Myers to Overweight from Equal Weight. The firm raised estimates above consensus and increased its price target on the stock to $80 from $60 following confirmation of Opdivo's survival benefits in lung cancer. Morgan Stanley expects Opdivo to be one of the top three pharma-bio launches over the next several years and notes Bristol is ahead of the competition in immuno-oncology combination drug development.
06:15 EDTBMYBristol-Myers upgraded to Overweight from Equal Weight at Morgan Stanley
Subscribe for More Information
April 20, 2015
08:12 EDTBMYVanda names Tom Gibbs as SVP and Chief Commercial OfficerBristol-Myers
Subscribe for More Information
07:20 EDTBMYAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information
06:02 EDTAZNClovis pullback on Astra data a buying opportunity, says Mizuho
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use